drug · antibody
tezepelumab
Marketedupdated 3mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.
indications
investigational
Asthma
targets
Thymic stromal lymphopoietin
all catalysts(4)
approval · 4
Dec 17, 2021
approval
$AZN164.49-0.28%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Feb 1, 2023
approval
$AZN164.49-0.28%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
May 26, 2023
approval
$AZN164.49-0.28%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Oct 17, 2025
approval
$AZN164.49-0.28%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Trials studying tezepelumab
- —Tezspire Cardiac Events PASS
- —Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- phase3Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
- phase3Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
- phase3A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that